AXIM BIOTECHNOLOGIES

PRESS RELEASES

LATEST NEWS & PRESS RELEASES

AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum

MarketWatch, January 18, 2017 – Axim enters a clinical trial for treating irritable bowel syndrome (IBS) with the company’s CanChew Plus(R) CBD gum at Wageningen University in the Netherlands.  The research team previously received approval from the Medical Ethical Committee (METC) of Wageningen University to study novel treatments for patients suffering from IBS.  See Full Article. . .

AXIM® Biotech Attends Biotech Showcase and J.P. Morgan Healthcare Conferences in San Francisco

MarketWatch, January 10, 2017 – AXIM announced that George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech is meeting with business prospects and investors at the Biotech Showcase 9 [th] Annual Conference and the J.P. Morgan 35 [th] Annual Healthcare Conference in San Francisco. See Full Article. . .

AXIM® Biotech Receives Positive PK Data Results for CanChew Plus® CBD Gum

MarketWatch, January 4, 2017 – Axim received positive pharmacokinetic (PK) data results on its CanChew Plus(R) CBD Gum, and gears up for clinical trial on alleviating the symptom of irritable bowel syndrome (IBS). The single dose study on 10 mg of cannabidiol (CBD) and 30 mg of CBD determined the concentration of CBD in the blood after chewing one CanChew Plus(R) Gum for thirty minutes in healthy volunteers. See Full Article. . .

AXIM® Biotech Expands Advisory Board to Broaden the Development of Cannabinoids’ Therapeutic Indications

MarketWatch, December 29, 2016 – Axim announced the addition of renowned Cardiac Anesthesiologist, Dr. Emil Engels MD, MBA, CPC. Dr. Emil Engel serves as Partner at Fairfax Anesthesiology Associates and American Anesthesiology of Virginia. See Full Article.

Axim® Biotech Announces Addition of World-Renowned Ophthalmologist to Advisory Board

GlobeNewswire,  December 27, 2016 – Axim added world-renowned surgeon and eye expert, Professor Robert Ritch to the Company’s Advisory Board. Prof. Ritch is the Surgeon Director Emeritus and Chief of Glaucoma Services at New York Eye and Ear Infirmary of Mount Sinai School of Medicine in New York (NYEE). See Full Article. . .

AXIM® Biotech Expands Advisory Board With Psychiatry Specialist, Dr. Ilya Reznik

MarketWatch, December 13, 2016 – Axim announced the addition to its Advisory Board of Dr. Ilya Reznik, a Board-certified specialist in Adult Forensic & Clinical Neuro Psychiatry at MaReNa Diagnostic and Consulting Center in Israel and a clinical practitioner utilizing medical cannabis inpatient treatment for over ten years. See Full Article

AXIM® Biotech Receives Medical Ethical Committee Approval to Begin IBS Trial for Canchew Plus® CBDGum

GlobeNewswire,  December 06, 2016 – AXIM announced today that it received approval from the Medical Ethical Committee (METC) of Wageningen University, The Netherlands, to begin a study on patients suffering from irritable bowel syndrome (IBS) with the Company’s CanChew Plus® CBD-containing chewing gum. See Full Article

AXIM® Biotech Selected by Fox Business as a “Top Five Biotech Stocks of 2016

Fox Business, November 29, 2016 – There have been better years for biotech stocks than 2016 has turned out to be. Concerns about a potential crackdown on excessive drug pricing cast a dark cloud over most drugmakers. However, despite headwinds for the broader industry, some biotech stocks performed very well. The “top five” list includes Axim Biotechnologies (NASDAQOTH: AXIM). Its stock has popped by more than 2,000% year to date, with most of those gains coming in the second half.  See Full Article

AXIM® Biotech Files IP Application on Proprietary Method to Extract High-Purity THC

GlobeNewswire,  November 29, 2016 – Axim announced today that it filed an IP application with the World Intellectual Property Organization (WIPO) on a proprietary method to extract THC-A (tetrahydrocannabinol acid) from cannabis plants and to achieve THC (tetrahydrocannabinol) with higher purity than conventional methods. See Full Article

Axim® Biotechnologies, Inc. Donates Flagship CanChew Gum to U.S. Pain Foundation to Help Chronic Pain Sufferers

GlobeNewswire, November 22, 2016 – Axim, a world leader in cannabinoid research and development, today announced that it donated 3,200 pieces of its hemp-derived CBD functional chewing gum CanChew® to the U.S. Pain Foundation to support the organization’s dedication in empowering caregivers and those who suffer from chronic pain. See Full Article

AXIM® Biotech Expands Patent Protection on Cannabinoid Chewing Gum — SECFilings.com

Marketwire, November 17, 2016 – SECFilings.com, a leading financial news and information portal offering free real-time public company filing alerts, announces an article on a new, extended patent for AXIM® Biotechologies’ (OTCQB:AXIM) cannabinoid-based chewing gum. See Full Article

New U.S. Patent Allowance Granted to AXIM® Biotech for Use of All Cannabinoids in Its Controlled-Release Chewing Gum Products

GlobeNewswire, November 16, 201 – Axim, a world leader in hemp cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 9,433,601, a patent that claims the use of all cannabinoids in cannabinoid-containing controlled-release chewing gum products. See Full Article

AXIM® Initiates New Studies & Pulls Ahead of the Competition — SECFilings.com

Marketwire,  November 07, 2016 – SECFilings.com, a leading financial news and information portal offering free real-time public company filing alerts, announces an article taking a closer look at AXIM Biotechnologies’ (OTCQB:AXIM) cannabinoid-based clinical trials program. See Full Article

Axim Biotechnologies Inc (OTCMKTS:AXIM) Looks Well Supported To Capitalize On Further Upside Potential

Insider Financial November 4, 2016 – Axim Biotechnologies Inc is running up up on news of its development pipeline advancing in some key early stage studies, and the company is drawing plenty of speculative capital as a result. There’s a lot of capital flowing into the marijuana space right now, much of it erroneous in advance of the spate of near term legalization votes, and so we thought we’d take a look at the catalysts behind Axim’s run in an attempt to identify whether or not the gains are warranted. See Full Article

Biotech Bets on the Booming Global Cannabis Industry

MoneyShow.Com November 04, 2016 – Although the biotech sector will be one of the greatest beneficiaries of the legal cannabis movement, the sector has recently been under pressure and this weakness has created significant opportunities for investors says Michael Berger, Editor of MoneyShow.com who highlights a few of the companies focused on this opportunity. See Full Article

AXIM® Biotechnologies, Inc. Posts Product Pipeline Chart for Pharmaceutical Clinical Trials Program in Cannabinoid R&D

Nasdaq Globe Newswire, November 03, 2016 – NEW YORK, Nov. 03, 2016 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has published a product pipeline chart on its website that highlights the timelines from pre-clinical to a new drug application (NDA) for its numerous intellectual property-protected cannabinoid-based products. See Full Article

AXIM Biotechnologies, Inc. CEO Speaks on Emerging Markets and Cannabis Drug Market at Money Show Dallas

Nasdaq Globe Newswire, October 19, 2016 – NEW YORK, Oct. 19, 2016 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, announced that its Chief Executive Officer George E. Anastassov, MD, DDS, MBA, spoke at The Money Show Dallas about emerging cannabis markets and in particular the cannabis drug market. The Money Show Dallas took place Oct. 19-21 at the Hyatt Regency in Dallas. It is a conference for investors and traders in search of opportunities for diversification and profits across the globe. See full article

AXIM Biotechnologies, Inc. CEO to Speak at First-Ever National Symposium on Medical Cannabis for Healthcare Professionals in Mexico City

Nasdaq Globe Newswire, October 6. 2016 – NEW YORK, — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development announced that its Chief Executive Officer George E. Anastassov, MD, DDS, MBA, will speak at the first-ever symposium dedicated to providing the medical community of Mexico with information about the medical value of cannabidiol (CBD) derivatives in Mexico City on Oct. 8. See Full Article

AXIM® Biotech Signs Exclusive Distribution Agreement With Israel’s Rafa Pharmaceuticals

Nasdaq Globe Newswire, September 2016 – NEW YORK, Sept. 19, 2016 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM), an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products, announced that it signed an exclusive distribution agreement with Israel-based Rafa Laboratories, Ltd. for distribution of its award-winning cannabinoid chewing gum CanChew.®  See Full Article

AXIM® Biotech to Begin Human Clinical Trials on CBG for Psoriasis

FORBES, May 17, 2016 – An in-depth article that covers human dermatological clinical trials for Cannabinoid based solutions for psoriasis and eczema at the Maurits Clinic in The Hague, The Netherlands.

Can Marijuana Save Your Skin—And Your Sex Life? Inside the New Topical Cannabis Phenomenon

Vogue.com, March 30, 2016 – The article mentions AximBioTech’s Oraximax, a forthcoming oral-care line that taps into the antibacterial and anti-inflammatory properties of the cannabinoid CBG.

AXIM Biotechnologies, Inc. Increases CanChew Cannabidiol (CBD) Gum Donations By 200%

Nasdaq Globe Newswire, July 2016 – AXIM® Biotechnologies, Inc. (AXIM® Biotech), a world leader in hemp cannabinoid research and development, launched the Company’s community outreach and legacy customer reward program.  AXIM® Biotech selected Adopt-A-Soldier Platoon, Inc. as a charitable giving beneficiary that will distribute 3,600 units of award-winning CanChew®cannabidiol (CBD) controlled release chewing gum to U.S. Veterans.  AXIM® also expanded the Company’s appreciation program to include legacy customers.  In total, AXIM increased product donations by 200% year-over-year and is distributing all products in the month of July.

AXIM® bags pot discount for gum to treat multiple sclerosis

Reuters, January 2016 – AXIM Biotechnologies Inc, a small, Manhattan-based company with ties to the Netherlands, says it has a trump card in its quest to develop a cannabis-based chewing gum to ease the symptoms of multiple sclerosis. The company says it will be able to price its gum cheaper than a major competitor after securing a “significant” discount on cannabis.

AXIM® Biotech CEO Appointed to American Pain Association Board of Advisors, Addresses American Opioid Abuse Epidemic

 Nasdaq Globe Newswire, March 2016 – NEW YORK, March 31, 2016– Dr. George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM ® Biotechnologies, Inc. was recently appointed to the American Pain Association’ s Board of Advisors. …

AXIM® Biotech Leads Cannabis Industry in Cannabinoid Research, Development and Intellectual Property; Tackles 15 Debilitating Conditions With No Known Cure

 Nasdaq Globe Newswire, February 2016 – NEW YORK, Feb. 18, 2016– Dr. George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM ® Biotechnologies, Inc. shares the hemp innovator’ s vision and actions that position the Company as …

For more information on AXIM‘s Latest News & Press Releases click the button below:

Enter your email address below
to receive investment news

Email *

Click button to view additional
investment news on Yahoo

AXIM AT YAHOO Finance

AIM RULE 26

AIM RULE 26

The contained information is disclosed in accordance with Rule 26 of the AIM regulations.

SECURITIES IN ISSUE

SECURITIES IN ISSUE

The percentage of the Company's issued share capital that is not in public hands.

SEC FILINGS

SEC FILINGS

Here you will find a collection of Axim’s SEC filings.